Diamyd is under clinical development by Diamyd Medical and currently in Phase III for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase III drugs for Type 1 Diabetes (Juvenile Diabetes) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Diamyd’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diamyd overview

Diamyd is under development for the treatment of LADA (latent autoimmune diabetes in adults), prevention and treatment of type 1 diabetes. It is an antigen-specific immunomodulatory therapeutic which is administered through subcutaneous, intra-inguinal and intralymphatic route. Diamyd consists of recombinant human GAD65 which acts by targeting pancreatic beta cell autoantigen in autoimmune diabetes. It is being developed based on GAD platform.

Diamyd Medical overview

Diamyd Medical (Diamyd), formerly Diamyd Therapeutics, is a drug development company that offers diabetes vaccines. The company’s diabetes products include Diamyd and Remygen. The company product Diamyd is antigen-based immunotherapy. Its other product includes remygen is a regenerative and immunomodulatory therapy. The company products are used for the treatment of autoimmune diabetes. Its products are in the clinical stage, Diamyd is at III stage and remygen is at II stages of development. The company drug has to pass several development stages such as preclinical and clinical phases. It does clinical trials of rugs in its facilities in Stockholm and umea, Sweden. Diamyd is headquartered in Stockholm, Sweden.

For a complete picture of Diamyd’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.